Laguna Tech
Medical device company developing transcatheter aortic valve systems and delivery platforms. Activities described on the site include valve and delivery system design, tissue processing, in‑house manufacturing in Class 5/7 cleanrooms, and conduct of first‑in‑human and feasibility clinical studies for investigational transcatheter heart valves.
Industries
N/A
Nr. of Employees
small (1-50)
Patents
Prosthetic heart valve device, delivery system, interventional system and related method
US-12226313-B2
View Details
Prosthetic heart valve device, delivery system, interventional system and related method
US-12226313-B2
View DetailsProducts
Balloon-expandable transcatheter aortic valve system
A balloon-expandable transcatheter aortic valve implant designed with multiple expanding support arms, low valve height, and a low-profile covered delivery system intended to treat aortic regurgitation and stenosis in a feasibility clinical setting.
Self-expanding transcatheter aortic valve system
A one-piece self-expanding transcatheter valve engineered with a low profile, multiple support arms for positioning, and a small-diameter delivery system intended for investigational treatment of aortic regurgitation.
Balloon-expandable transcatheter aortic valve system
A balloon-expandable transcatheter aortic valve implant designed with multiple expanding support arms, low valve height, and a low-profile covered delivery system intended to treat aortic regurgitation and stenosis in a feasibility clinical setting.
Self-expanding transcatheter aortic valve system
A one-piece self-expanding transcatheter valve engineered with a low profile, multiple support arms for positioning, and a small-diameter delivery system intended for investigational treatment of aortic regurgitation.
Services
Manufacture and assembly of valve implants and delivery systems in certified Class 5 and Class 7 cleanrooms with processes oriented for clinical scale-up.
Manufacture and assembly of valve implants and delivery systems in certified Class 5 and Class 7 cleanrooms with processes oriented for clinical scale-up.
Expertise Areas
- Transcatheter heart valve design
- Delivery system engineering for TAVR
- Cleanroom-based device manufacturing and scale-up
- Tissue processing for valve implants
Key Technologies
- Balloon-expandable transcatheter valve design
- Self-expanding transcatheter valve design
- Low-profile delivery catheter architecture (16F access)
- Deflectable and steerable delivery catheters
News & Updates
Announcement that first-in-human clinical case was completed and additional patients treated with an investigational self-expanding valve system; reported complete resolution of aortic regurgitation maintained at 30-day follow-up for two patients.
Report that the first patient was treated in a first-in-human feasibility trial of an investigational self-expanding transcatheter aortic valve to treat aortic regurgitation; 30-day follow-up outcome reported for the first patient.
Announcement that five patients were treated at a single center on the same day in an ongoing feasibility trial for an investigational balloon-expandable transcatheter valve; reported immediate procedural resolution and 24–48 hour discharge for those cases.
Site-reported set of clinical cases (including six reported cases with 30–60 day follow-up) in feasibility/first-in-human studies showing resolution of aortic regurgitation immediately post-procedure.
Announcement of a granted U.S. patent (US 11,806,233) strengthening the company's intellectual property position in the transcatheter valve space.
Announcement that first-in-human clinical case was completed and additional patients treated with an investigational self-expanding valve system; reported complete resolution of aortic regurgitation maintained at 30-day follow-up for two patients.
Report that the first patient was treated in a first-in-human feasibility trial of an investigational self-expanding transcatheter aortic valve to treat aortic regurgitation; 30-day follow-up outcome reported for the first patient.
Announcement that five patients were treated at a single center on the same day in an ongoing feasibility trial for an investigational balloon-expandable transcatheter valve; reported immediate procedural resolution and 24–48 hour discharge for those cases.
Site-reported set of clinical cases (including six reported cases with 30–60 day follow-up) in feasibility/first-in-human studies showing resolution of aortic regurgitation immediately post-procedure.
Announcement of a granted U.S. patent (US 11,806,233) strengthening the company's intellectual property position in the transcatheter valve space.